To estimate the clinical potential of RSL3 in treating MM we additionally investigated mutp53(E285K)-expressing SkMel29 and mutp53(R248Q) gain-of-function expressing WM1552C MM cell lines (https://p53.fr/tp53-database/the-tp53-cell-line-compendium), both being largely resistant to cisplatin as well as to re-sensitization with PRIMA1-Met (Fig. S8). This evidence concerns the gene PRIMA1 and Miyoshi myopathy.